Deals
Pfizer Confirms Termination of Proposed $160 Billion Allergan Merger
- Allergan CEO now says he's on the lookout for another merger
- Deal's failure praised by Democratic presidential candidates
Allergan CEO: Feds Rules Aimed at Stopping the Inversion
This article is for subscribers only.
The biggest deal in drug industry history is dead.
Pfizer Inc. and Allergan Plc terminated their $160 billion merger on Wednesday after the U.S. government proposed regulations to crack down on corporate tax inversions, stymieing New York-based Pfizer’s long effort to get out from under the highest corporate tax rate in the developed world.